Ionis Pharmaceuticals, Inc. IONS · Stock Open Ionis Pharmaceuticals, Inc. in new tab
Ionis Pharmaceuticals, Inc. Analysis (IONS)
Is Ionis Pharmaceuticals, Inc. a good investment? Ionis Pharmaceuticals, Inc. (IONS) is currently trading at 73.28 USD. Market analysts have a consensus price target of 100.92 USD. This suggests a potential upside from current levels.
Earnings Schedule: Ionis Pharmaceuticals, Inc. is expected to release its next earnings report on July 29, 2026. The market consensus estimate for Forward EPS is -0.62.
Investor FAQ
Does Ionis Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Ionis Pharmaceuticals, Inc.?
Ionis Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 5 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 29, 2026. The company currently has a trailing EPS of -2.01.
Company Profile
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
Community Discussion